

**STRIDES PHARMA INTERNATIONAL LIMITED**  
**BALANCE SHEET AS AT MARCH 31, 2022**

		<b>Amount in USD</b>	<b>Amount in USD</b>
		<b>31-Mar-22</b>	<b>31-Mar-21</b>
<b>A ASSETS</b>			
<b>I Current assets</b>			
(a) Financial assets			
(i) Investments		25,000	330,000
(ii) Cash and cash equivalents	1	35,701	23,125
(iii) Loans	2	18,801,424	17,790,024
(b) Other current assets	3	4,149,948	4,140,143
<b>Total current assets</b>		<b>23,012,074</b>	<b>22,283,292</b>
 <b>TOTAL ASSETS</b>		<b>23,012,074</b>	<b>22,283,292</b>
 <b>B EQUITY AND LIABILITIES</b>			
<b>I Equity</b>			
(a) Equity share capital	4	438,000	438,000
(b) Other equity	5	14,504,850	13,672,604
<b>Total Equity</b>		<b>14,942,850</b>	<b>14,110,604</b>
 <b>1 Current liabilities</b>			
(a) Financial liabilities			
(i) Trade payables	6	19,651	698
(ii) Other financial liabilities	7	6,494,588	5,526,345
(b) Provisions	8	310,208	184,830
(c) Current income tax liabilities	9	1,244,777	2,460,816
<b>Total current liabilities</b>		<b>8,069,224</b>	<b>8,172,689</b>
 <b>TOTAL EQUITY AND LIABILITIES</b>		<b>23,012,074</b>	<b>22,283,293</b>

**STRIDES PHARMA INTERNATIONAL LIMITED**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2022**

	Particulars	Note No.	Amount in USD	Amount in USD
			31-Mar-22	31-Mar-21
1	Revenue from operations		-	-
2	Other Income	10	1,220,543	1,011,400
3	<b>Total Revenue (1+2)</b>		<b>1,220,543</b>	<b>1,011,400</b>
4	<b>Expenses</b>			
	(a) Finance costs	11	1,204	1,234
	(b) Other expenses	12	268,088	841,524
	<b>Total expenses</b>		<b>269,292</b>	<b>842,758</b>
5	<b>Profit / (Loss) before exceptional items and taxes (3-4)</b>		<b>951,251</b>	<b>168,642</b>
6	Exceptional Item		-	-
7	<b>Profit / (Loss) before taxes (5+6)</b>		<b>951,251</b>	<b>168,642</b>
8	<b>Tax Expense:</b>			
	(1) Current tax		119,005	102,140
	(2) Deferred tax		-	-
	Total tax expenses		119,005	102,140
9	<b>Profit / (Loss) for the year after tax</b>		<b>832,246</b>	<b>66,502</b>

**STRIDES PHARMA INTERNATIONAL LIMITED**  
**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED MARCH 31, 2022**

**(A) Equity share capital**

Particulars	Amount in USD
Balance as at March 31, 2021	438,000
Changes in equity share capital during the year	-
<b>Balance as at March 31, 2022</b>	<b>438,000</b>

**(B) Other equity**

Amount in USD

Particulars	Reserves and Surplus		Total
	Securities Premium	Retained earnings	
Balance as at March 31, 2021	(31,575,887)	45,248,491	12,771,386
Profit/loss for the year	-	832,246	832,246
Other comprehensive income for the year (net of tax)	-	-	-
<b>Total comprehensive income</b>	<b>(31,575,887)</b>	<b>46,080,737</b>	<b>13,603,632</b>
<b>Balance as at March 31, 2022</b>	<b>(31,575,887)</b>	<b>46,080,737</b>	<b>13,603,632</b>

STRIDES PHARMA INTERNATIONAL LIMITED

Notes forming part of financial statement

Note

No.

1	Cash and cash equivalents	Amount in USD	
	Particulars	31-Mar-22	31-Mar-21
	Balances with banks:		
	In current accounts	35,701	23,125
	<b>Total</b>	<b>35,701</b>	<b>23,125</b>
2	Loans	Amount in USD	
	Particulars	31-Mar-22	31-Mar-21
	Loans	18,801,424	17,790,024
	<b>Total</b>	<b>18,801,424</b>	<b>17,790,024</b>
3	Other current assets	Amount in USD	
	Particulars	31-Mar-22	31-Mar-21
	<b>Unsecured, considered good</b>		
	Loans and advances to Group entities	4,149,948	4,140,143
	<b>Total</b>	<b>4,149,948</b>	<b>4,140,143</b>
4	Share capital	Amount in USD	
	Particulars	31-Mar-22	31-Mar-21
	Issued, subscribed and fully paid-up		
	Equity share capital	438,000	438,000
	<b>Total</b>	<b>438,000</b>	<b>438,000</b>
5	Reserves and surplus	Amount in USD	
	Particulars	31-Mar-22	31-Mar-21
	<b>Securities premium account</b>		
	Opening balance	(31,575,887)	(31,575,887)
	Add : Premium on shares issued during the year	-	-
	<b>Closing balance</b>	<b>(31,575,887)</b>	<b>(31,575,887)</b>
	<b>Surplus in statement of profit and loss</b>		
	Opening balance	45,248,491	44,347,274
	Add: Profit / (Loss) for the year	832,246	901,217
	<b>Closing balance</b>	<b>46,080,737</b>	<b>45,248,491</b>
	<b>Total</b>	<b>14,504,850</b>	<b>13,672,604</b>
6	Trade payables	Amount in USD	
	Particulars	31-Mar-22	31-Mar-21
	Trade payable	19,651	698
	<b>Total</b>	<b>19,651</b>	<b>698</b>
7	Other Current financial Liabilities	Amount in USD	
	Particulars	31-Mar-22	31-Mar-21
	Payable to group entities	6,486,254	5,526,345
	Other payables:		
	- Statutory remittances	8,334	-
	<b>Total</b>	<b>6,494,588</b>	<b>5,526,345</b>

STRIDES PHARMA INTERNATIONAL LIMITED

Notes forming part of financial statement

Note

No.

8 Provisions

Amount in USD

Particulars	31-Mar-22	31-Mar-21
Provision for expenses	310,208	184,830
<b>Total</b>	<b>310,208</b>	<b>184,830</b>

9 Current Income tax liability

Amount in USD

Particulars	31-Mar-22	31-Mar-21
Provision for income tax (net of advance tax)	1,244,777	2,460,816
<b>Total</b>	<b>1,244,777</b>	<b>2,460,816</b>

**STRIDES PHARMA INTERNATIONAL LIMITED**

**Notes forming part of financial statement**

**Note**

**No.**

**10 Other Income** **Amount in USD**

Particulars	31-Mar-22	31-Mar-21
Exchange fluctuation gain	209,143	-
Other Interest Income	1,011,400	1,011,400
<b>Total</b>	<b>1,220,543</b>	<b>1,011,400</b>

**11 Finance cost** **Amount in USD**

Particulars	31-Mar-22	31-Mar-21
Bank charges	1,204	1,234
<b>Total</b>	<b>1,204</b>	<b>1,234</b>

**12 Other expenses** **Amount in USD**

Particulars	31-Mar-22	31-Mar-21
Rates & taxes	588	20,711
Provision for impairment of Assets	305,000	-
Director Sitting Fess	2,111	-
Net loss on foreign currency transactions	-	461,248
Professional fees	7,450	345,713
Payment to Auditors - For Statutory Audit	12,938	13,852
Miscellaneous Expense	(60,000)	-
<b>Total</b>	<b>268,088</b>	<b>841,524</b>